Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

Saagar N Patel; Mona L Camacci; Esther M Bowie

doi:10.1159/000519275

Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

Case Rep Ophthalmol. 2022 Feb 11;13(1):57-63. doi: 10.1159/000519275. eCollection 2022 Jan-Apr.

Authors

Saagar N Patel¹, Mona L Camacci¹, Esther M Bowie¹

Affiliation

¹ Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, USA.

Abstract

We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovitelliform lesions in both eyes 6 weeks after initiation of erdafitinib. After discontinuation of this drug, his visual complaints resolved and his lesions decreased on optical coherence tomography. To our knowledge, this is the first case depicting reversible macular lesions with use of this newly approved medication outside of clinical trial protocols.

Keywords: Fibroblast growth factor receptor; Fibroblast growth factor receptor retinopathy; Mitogen-activated protein kinase; Mitogen-activated protein kinase kinase associated retinopathy; Optical coherence tomography.

Publication types

Case Reports